scholarly journals Assessment of the receptor status in primary breast cancer with synchronous loco regional metastases: prognostic and clinical role?

2019 ◽  
Vol 18 (2) ◽  
pp. 78-82
Author(s):  
O. O. Gordeeva ◽  
L. G. Zhukova ◽  
I. V. Kolyadina ◽  
I. P. Ganshina
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Hormone Receptor ◽  
Primary Breast Cancer ◽  
Locally Advanced ◽  
Metastatic Breast ◽  
Hormone Receptor Status ◽  
Primary Tumors ◽  
Receptor Status ◽  
Regional Metastases

Background. Assessment of hormone receptor status plays a crucial role in treatment of patients with breast cancer. currently, clinicians are limited to determining the expression status of estrogen receptor (ER), progesterone receptor (pR) and HER2 only in primary breast cancer tissues, even in the presence of regional metastases.The purpose of the study was to review available data on heterogeneity of ER, pR and HER2/neu expressions in primary breast cancer and regional metastases.Material and methods. We analyzed publications available from pubmed, medline etc. using the keywords «discordance», «breast cancer», «locally advanced», «regional lymph nodes», «ER», «pR», and «HER2».Results. The clinical and prognostic role in assessing the heterogeneity of the receptor status of primary tumors and synchronous regional metastases, as well as the effect of detected discordance on treatment tactics was assessed.Conclusion. Data on the frequency of discordance in hormone receptor status between primary and metastatic breast cancer tumors and its effect on the further prognosis in breast cancer are still contradictory. However, the fact of the presence of such heterogeneity suggests that some patients with affected lymph nodes will have significant benefits from determining the status of steroid hormones and HER2 not only in the primary tumor, but also in the lymph nodes, since it will open up new opportunities for subsequent targeted therapy.

Hormone receptor status in primary breast cancer—time for a consensus?

2002 ◽  
Vol 38 (9) ◽  
pp. 1201-1203 ◽  
Author(s):  
G.C Wishart ◽  
M Gaston ◽  
A.A Poultsidis ◽  
A.D Purushotham
Keyword(s):  
Breast Cancer ◽  
Hormone Receptor ◽  
Primary Breast Cancer ◽  
Hormone Receptor Status ◽  
Receptor Status

Analysis of Metastatic Involvement of Interpectoral (Rotter's) Lymph Nodes Related to Tumor Location, Size, Grade and Hormone Receptor Status in Breast Cancer

2005 ◽  
Vol 91 (2) ◽  
pp. 177-181 ◽  
Author(s):  
Danko Velimir Vrdoljak ◽  
Vesna Ramljak ◽  
Dubravka Mužina ◽  
Božena Šarčeviç ◽  
Fabijan Knežević ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Lymph Nodes ◽  
Hormone Receptor ◽  
Serum Levels ◽  
Tumor Location ◽  
Hormone Receptor Status ◽  
Axillary Lymph Nodes ◽  
Axillary Lymph ◽  
Receptor Status ◽  
Metastatic Involvement

Aims and background This study was aimed at analyzing metastatic involvement in interpectoral (Rotter's) lymph nodes in relation to tumor location, size, grade and hormone receptor status in primary breast cancer. Methods The study included 172 female patients undergoing surgery for breast cancer at the University Hospital for Tumors, Zagreb, Croatia from November 2001 to August 2003. In addition to the standard surgical procedure, interpectoral (Rotter's) lymph nodes were removed in all of the patients. Serum levels of the tumor marker CA 15-3 were determined before surgery and hormone receptor status after surgery. Results Rotter's lymph nodes were identified in 67% of the patients, with metastatic involvement being found in 20% of the Rotter's nodes. Metastatic involvement of Rotter's nodes in patients with negative and positive axillary lymph nodes was 4% and 35%, respectively. When we looked at the location of the tumor in patients with metastatic involvement of Rotter's nodes, we found that tumors located in the upper quadrants were more prone to metastasis to Rotter's nodes; there was a significant positive correlation between tumor location and positive Rotter's nodes (r = 0.953, P = 0.012). As regards tumor size, Rotter's nodes were identified in 15%, 20% and 30% of stage T1 (<2 cm), T2 (2-5 cm) and T3 (>5 cm) tumors, respectively. Hormone receptor status showed no statistically significant difference in the expression of estrogen and progesterone receptors between patients with and those without positive Rotter's nodes. Of 35 Rotter's node-positive patients, 31.4% had elevated serum levels of CA 15-3; the level was significantly higher in Rotter's-positive patients compared to those with negative (or absent) Rotter's nodes. Conclusions The results show that one-fifth of breast cancer patients, or even one-third of those with positive axillary lymph nodes, are discharged with positive interpectoral lymph nodes that remain undiagnosed. As the nodes can be surgically removed without additional mutilation, exploration of Rotter's lymph nodes should be introduced into routine clinical practice.

Prognostic factors for survival in metastatic breast cancer by hormone receptor status

2014 ◽  
Vol 145 (2) ◽  
pp. 503-511 ◽  
Author(s):  
A. B. G. Kwast ◽  
A. C. Voogd ◽  
M. B. E. Menke-Pluijmers ◽  
S. C. Linn ◽  
G. S. Sonke ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Prognostic Factors ◽  
Metastatic Breast Cancer ◽  
Hormone Receptor ◽  
Metastatic Breast ◽  
Hormone Receptor Status ◽  
Receptor Status

scholarly journals SURVIVAL COMPARISON OF HER2 METASTATIC BREAST CANCER PATIENTS ACCORDING TO HORMONE RECEPTOR STATUS: PORTUGUESE MULTICENTER EXPERIENCE

The Breast ◽  
2021 ◽  
Vol 59 ◽  
pp. S51
Author(s):  
Rita Gameiro-dos-Santos ◽  
Paulo Luz ◽  
Isabel G. Fernandes ◽  
João Gramaça ◽  
Carolina Trabulo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Hormone Receptor ◽  
Metastatic Breast ◽  
Hormone Receptor Status ◽  
Breast Cancer Patients ◽  
Receptor Status

Effects of hormone receptor status on the durable response of trastuzumab-based therapy in metastatic breast cancer

2017 ◽  
Vol 163 (2) ◽  
pp. 255-262 ◽  
Author(s):  
Hyung Soon Park ◽  
Joohyuk Sohn ◽  
Seung Il Kim ◽  
Seho Park ◽  
Hyung Seok Park ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Hormone Receptor ◽  
Metastatic Breast ◽  
Hormone Receptor Status ◽  
Durable Response ◽  
Receptor Status

Discordant ER, PR, and HER2 status between primary and metastatic breast cancer as prognostic factor.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 1039-1039
Author(s):  
Hee-Chul Shin ◽  
Wonshik Han ◽  
Hyeong-Gon Moon ◽  
Seock-Ah Im ◽  
Woo Kyung Moon ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Triple Negative Breast Cancer ◽  
Primary Breast Cancer ◽  
Triple Negative ◽  
Cancer Survival ◽  
Metastatic Breast ◽  
Her2 Status ◽  
Primary Tumors ◽  
Receptor Status

1039 Background: The receptor status including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) of metastases may be different from that of the primary breast cancer. This discordance of receptor status may influence patient prognosis. We investigated discordance of receptor status between primary breast cancer and distant metastases in the same patients and its effect on prognosis. Methods: ER, PR, and HER2 status in metastases were available in 173 patients. The receptor status was compared between primary tumors and metastases. Tumors were classified as triple-negative breast cancer (TNBC) or non-triple-negative breast cancer (non-TNBC) according to receptor status and as concordant and discordant depending on the difference of receptor status between primary and metastatic breast cancer. Survival analysis was performed depending on concordant or discordant receptor status. Results: Discordance for ER, PR, and HER2 was 18.5%, 23.7%, and 10.4%, respectively. Concordant non-TNBC and TNBC between primary tumors and metastases was 69.9% and 17.9%, respectively. Discordant TNBC was 12.1%. On multivariate analysis, patients with discordant TNBC had unfavorable survival compared with patients with concordant non-TNBC (relative risk 2.544, 95% confidence interval, 1.220-5.303, p = 0.013). The median survival after recurrence was 41.8 months for patients with concordant non-TNBC, 20.7 months for patients with concordant TNBC, and 19.9 months for patients with discordant TNBC (p < 0.0001). Conclusions: The change of ER, PR, and HER2 status between primary and metastatic tumors occur and discordant TNBC is associated with poor survival.

Sign in / Sign up

Export Citation Format

Share Document